Table 2.

Characteristics of initial irAEs

RetreatmentDiscontinuationP
Grade of the first irAE, N (%)0.01
 Grades 1 and 225 (66)10 (33)
 Grades 3 and 413 (34)20 (67)
Type of irAE; N (%)0.62a
 Pneumonitis6 (16)7 (23)
 Colitis7 (18)5 (17)
 Rash/pruritus5 (13)6 (20)
 ALT or AST increase3 (8)4 (13)
 Arthralgia/myalgia5 (13)1 (3)
 Nephritis2 (5)2 (7)
 Pancreatic enzymes elevation4 (11)0 (0)
 Meningitis/headache2 (5)1 (3)
 Endocrine disordersb2 (5)1 (3)
 Ventricular arrhythmias1 (3)0 (0)
 Fatigue1 (2)0 (0)
 ITP0 (0)1 (3)
 Other0 (0)2 (7)
Hospitalizations, N (%)8 (21)16 (53)0.01
Time interval to irAE:
 Days, median (range)69 (14–577)73 (2–452)0.77
No. infusions before the irAE:
 No., median (range)4.5 (1–42)5.5 (1–27)0.51
Corticosteroid used, N (%)29 (76)29 (97)0.03
 Intravenous3 (10)12 (40)
 Oral23 (80)16 (53)
 Otherc3 (10)2 (6)
Steroids > 4 weeks, N (%)10 (34)15 (65)d0.04
Anti-TNF used in the first toxicity, N (%)0 (0)3 (9)0.05
irAE resolved to, N (%)0.03
 Grades 0 and 137 (97)23 (79)
 Grade ≥ 21 (3)6 (21)
Death related to irAE; N (%)02
  • Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; ITP, idiopathic thrombocytopenic purpura; Anti-TNF, antitumor necrosis factor alpha.

  • aThis P value refers to the comparison of the four more common toxicities.

  • bHypothyroidism (n = 1), hyperthyroidism (n = 1), and adrenal insufficiency (n = 1).

  • cTopical steroids or nonabsorbable budesonide.

  • dThere are 6 patients who were not evaluable for this category for reasons such as death, loss of follow-up, and noncompliance.